PAVmed (NASDAQ:PAVM – Get Free Report) had its price objective dropped by investment analysts at Ascendiant Capital Markets from $19.50 to $19.00 in a research report issued on Friday,Benzinga reports. The firm presently has a “buy” rating on the stock.
PAVmed Trading Up 3.0%
NASDAQ:PAVM opened at $0.63 on Friday. The company has a market cap of $10.79 million, a price-to-earnings ratio of -0.15 and a beta of 1.11. PAVmed has a twelve month low of $0.55 and a twelve month high of $1.90. The stock has a fifty day simple moving average of $0.68 and a 200-day simple moving average of $0.72.
Institutional Trading of PAVmed
An institutional investor recently raised its position in PAVmed stock. First Manhattan CO. LLC. raised its position in shares of PAVmed Inc. (NASDAQ:PAVM – Free Report) by 16.7% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 700,000 shares of the company’s stock after purchasing an additional 100,000 shares during the period. First Manhattan CO. LLC. owned about 6.32% of PAVmed worth $439,000 as of its most recent filing with the Securities & Exchange Commission. 19.93% of the stock is currently owned by institutional investors and hedge funds.
PAVmed Company Profile
PAVmed Inc focuses on acquiring, developing, and commercializing novel products that target unmet needs in the United States. The company's lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; EsoCheck Esophageal Cell Collection Device, which consists of diagnostic test that serves as a testing tool for preventing esophageal adenocarcinoma deaths, through early detection of esophageal precancer in at-risk gastroesophageal reflux disease, including chronic heartburn and acid reflux or simply reflux in patients; and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay performed on surface esophageal cells collected with EsoCheck.
Read More
- Five stocks we like better than PAVmed
- Insider Trading – What You Need to Know
- 3 Top Dividend Stocks Analysts Are Bullish on Right Now
- Business Services Stocks Investing
- 5 Earnings Season Winners With More Upside on the Way
- Best Stocks Under $5.00
- Is Meta Plotting a Stablecoin Comeback Years After Libra’s Flop?
Receive News & Ratings for PAVmed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PAVmed and related companies with MarketBeat.com's FREE daily email newsletter.
